Natco Pharma gets regulatory nod for Chlorantraniliprole
Hyderabad: Natco Pharma Limited has recently announced the company's registration approval given by Central Insecticide Board & Registration Committee (CIB&RC) recorded in its Minutes of the 425th Meeting held on 25.01.2021, for indigenous manufacture of Chlorantraniliprole (CTPR) Technical 93.00% w/ w min. under Section 9(3) of Insecticides Act, 1968.
NATCO would be the 1st indigenous manufacturer of this technical product, the company said.
CTPR technical is formulated into broad-spectrum insecticides used in several crops for better pest management. NATCO hopes to bring products based on CTPR shortly that would be affordable and accessible to farmers across India.
CTPR is an active ingredient used in products commercialized by FMC under brands Coragen & Ferterra. The sales generated from CTPR containing products in India, inclusive of third-party marketing companies, as per declaration given by FMC was estimated to be INR 1540 crores in 2016.
The Company believes the current market size to be over INR 2000 crores, Natco added.
NATCO has a pending litigation against FMC for declaration of freedom to use of CTPR.
The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.